Charges Billed to Third Parties for Prescription Drugs Furnished by VA to a Veteran for a Nonservice-Connected Disability, 61621-61623 [2010-25043]
Download as PDF
Federal Register / Vol. 75, No. 193 / Wednesday, October 6, 2010 / Rules and Regulations
List of Subjects in 33 CFR Part 165
Harbors, Marine safety, Navigation
(water), Reporting and recordkeeping
requirements, Security measures,
Waterways.
■ For the reasons discussed in the
preamble, the Coast Guard amends 33
CFR part 165 as follows:
PART 165—REGULATED NAVIGATION
AREAS AND LIMITED ACCESS AREAS
1. The authority citation for part 165
continues to read as follows:
■
Authority: 33 U.S.C. 1226, 1231; 46 U.S.C.
Chapter 701, 3306, 3703; 50 U.S.C. 191, 195;
33 CFR 1.05–1, 6.04–1, 6.04–6, and 160.5;
Pub. L. 107–295, 116 Stat. 2064; Department
of Homeland Security Delegation No. 0170.1.
may be contacted on VHF–FM Channel
16.
(3) All persons and vessels must
comply with the instructions of the
Coast Guard Captain of the Port or his
designated representative.
(4) Upon being hailed by U.S. Coast
Guard patrol personnel by siren, radio,
flashing light, or other means, the
operator of a vessel must proceed as
directed.
(5) The Coast Guard may be assisted
by other federal, state, or local agencies.
Dated: September 17, 2010.
P.J. Hill,
Commander, U.S. Coast Guard, Acting
Captain of the Port San Diego.
[FR Doc. 2010–25193 Filed 10–5–10; 8:45 am]
BILLING CODE 9110–04–P
2. Add a new temporary § 165.T11–
182 to read as follows:
■
WReier-Aviles on DSKGBLS3C1PROD with RULES
§ 165.T11–182 Safety Zone; IJSBA World
Finals; Lower Colorado River, Lake Havasu,
AZ.
(a) Location. The following area is a
safety zone: All waters of Lake Havasu,
from surface to bottom, encompassed by
lines connecting the following points:
Beginning at 34°28.49′ N, 114°21.33′ W;
thence to 34°28.55′ N, 114°21.56′ W;
thence to 34°28.43′ N, 114°21.81′ W;
thence to 34°28.32′ N, 114°21.71′ W;
thence along the shoreline returning to
34°28.49′ N, 114°21.33′ W.
These coordinates are based upon
NAD 83.
(b) Enforcement Period. This section
will be enforced from sunrise to sunset
on October 3, 2010 through October 10,
2010. If the International Jet Sports
Boating Association World Finals
concludes prior to the scheduled
termination of the effective period, the
Captain of the Port will cease
enforcement of this safety zone and will
announce that fact via Broadcast Notice
to Mariners.
(c) Definitions. The following
definition applies to this section:
Designated representative means any
Commissioned, Warrant, or Petty
Officers of the Coast Guard or Coast
Guard Auxiliary, and local, state, and
federal law enforcement officers who
have been authorized to act on the
behalf of the Captain of the Port.
(d) Regulations. (1) Under the general
regulations in § 165.23, entry into,
transit through or anchoring within this
safety zone is prohibited unless
authorized by the Captain of the Port
San Diego or his designated
representative.
(2) Mariners desiring to enter or
operate in the safety zone may request
authorization to do so from the Patrol
Commander (PATCOM). The PATCOM
VerDate Mar<15>2010
15:06 Oct 05, 2010
Jkt 223001
DEPARTMENT OF VETERANS
AFFAIRS
38 CFR Part 17
RIN 2900–AN15
Charges Billed to Third Parties for
Prescription Drugs Furnished by VA to
a Veteran for a Nonservice-Connected
Disability
Department of Veterans Affairs.
Final rule.
AGENCY:
ACTION:
This document amends the
medical regulations of the Department
of Veterans Affairs (VA) concerning
‘‘reasonable charges’’ for medical care or
services provided or furnished by VA to
a veteran for a nonservice-connected
disability. More specifically, VA
amends the regulations regarding
charges billed for prescription drugs not
administered during treatment by
changing the billing formula to reflect
VA’s actual drug costs for each drug
rather than using a national average
drug cost for all prescriptions
dispensed. The revised formula for
calculating reasonable charges for
prescription drug costs will also
continue to include an average
administrative cost for each
prescription. The purpose is to provide
VA with a more accurate billing
methodology for prescription drugs.
DATES: Effective Date: This final rule is
effective on March 18, 2011.
Applicability Date: The final rule will
apply to prescriptions filled on or after
March 18, 2011.
FOR FURTHER INFORMATION CONTACT:
Romona Greene, Manager of Rates and
Charges, VHA Chief Business Office
(168), Veterans Health Administration,
Department of Veterans Affairs, 810
Vermont Avenue, NW., Washington, DC
SUMMARY:
PO 00000
Frm 00033
Fmt 4700
Sfmt 4700
61621
20420, (202) 461–1595. (This is not a
toll-free number.)
SUPPLEMENTARY INFORMATION: Under 38
U.S.C. 1729, VA has the right to recover
or collect reasonable charges for medical
care or services (including the provision
of prescription drugs) from a third party
to the extent that the veteran or the
provider of the care or services would
be eligible to receive payment from the
third party for:
• A nonservice-connected disability
for which the veteran is entitled to care
(or the payment of expenses of care)
under a health plan contract, 38 U.S.C.
1729(a)(2)(D), 38 CFR 17.101(a)(1)(i);
• A nonservice-connected disability
incurred incident to the veteran’s
employment and covered under a
worker’s compensation law or plan that
provides reimbursement or
indemnification for such care and
services, 38 U.S.C. 1729(a)(2)(A), 38
CFR 17.101(a)(1)(ii); or
• A nonservice-connected disability
incurred as a result of a motor vehicle
accident in a State that requires
automobile accident reparations (nofault) insurance, 38 U.S.C. 1729(a)(2)(B),
38 CFR 17.101(a)(1)(iii).
However, under current 38 CFR
17.101(a)(4), which implements 38
U.S.C. 1729(c)(2)(B), a third-party payer
liable for such medical care and services
under a health plan contract has the
option of paying, to the extent of its
coverage, either the billed charges or the
amount the third-party payer
demonstrates it would pay for care or
services furnished by providers other
than entities of the United States for the
same care or services in the same
geographic area.
Prior to the effective date of this
document, VA billed for prescription
drugs not administered during treatment
based on the sum of two components:
(1) The national average of VA’s drug
costs for all prescriptions, and (2) the
national average of VA’s administrative
costs associated with furnishing
prescription drugs. Further, in
accordance with § 17.102(h), prior to the
effective date of this document, VA
billed $51 for each prescription filled
(see 70 FR 66866, Nov. 3, 2005).
In a document published in the
Federal Register on July 9, 2009 (74 FR
32819), we proposed to change the
billing methodology for prescription
drugs not administered during
treatment. With respect to the portion of
the billing concerning VA’s cost for
such prescription drugs, we proposed to
bill based on the actual cost to VA of
each prescription drug rather than the
national average of drug costs for all
prescriptions. In this regard, we
proposed to bill the total of:
E:\FR\FM\06OCR1.SGM
06OCR1
WReier-Aviles on DSKGBLS3C1PROD with RULES
61622
Federal Register / Vol. 75, No. 193 / Wednesday, October 6, 2010 / Rules and Regulations
• The actual cost to VA for
prescription drugs (i.e., the cost to the
facility that purchased the drugs); and
• The average national administrative
cost associated with dispensing the
drugs for each prescription.
We provided a 30-day comment
period that ended on August 10, 2009.
We received comments from three
commenters and the issues they raised
are discussed below. Based on the
rationale set forth in the proposed rule
and this document, we are adopting the
proposed rule with the nonsubstantive
changes discussed below.
Two commenters indicated that the
final rule should ensure that insurance
companies pay VA in response to VA
billing, and thereby reduce or eliminate
the veterans’ copayment. We agree that
the payment practices of third-party
payers need to be addressed. However,
those practices are not within the scope
of this rulemaking. This rulemaking
concerns VA’s methodology for
determining reasonable charges for
prescription drugs. We did not propose
to amend other VA regulations
regarding third-party payment
procedures or to promulgate new
regulations regarding such procedures.
However, we intend to separately
publish a proposed rule to address
issues regarding requirements for thirdparty payers making payments to VA.
Another commenter raised a number
of issues. All of these issues are
discussed below.
The commenter indicated that the VA
acquisition cost for prescription drugs
could be more than the third-party
payer cost for the same prescription
drugs and seemed to suggest that the
billing amount for the cost of the drugs
should not be more than the amount
that the third-party payer would be
required to pay for the same
prescription drugs. The commenter also
indicated that the VA administrative fee
of $11.17 is more than the average
private dispensing fee and that private
industry has been successful in
negotiating such fees in the range of
$1.50 to $2.00. We clarified what is
meant by administrative costs but made
no other changes based on these
comments.
Under the provisions of 38 U.S.C.
1729, VA has authority to bill thirdparty payers in an amount constituting
‘‘reasonable charges.’’ We believe that
the billing formula is warranted under
the statute. Moreover, VA has taken
steps to keep costs at a minimum.
In most cases VA purchases drugs in
bulk at discounted prices. Also, insofar
as possible, VA prescribes generic
drugs.
VerDate Mar<15>2010
15:06 Oct 05, 2010
Jkt 223001
Further, the $1.50 to $2.00 amounts
quoted by the commenter were
represented as negotiated fees and not
represented as covering the actual
administrative costs. We question
whether these negotiated fees include
all of the actual administrative costs.
The VA administrative costs include
general overhead costs, such as costs of
buildings and maintenance, utilities,
billing, and collections, and includes
dispensing costs, such as costs of the
labor of the pharmacy department,
packaging, and mailing.
Even so, in some cases, a third party
payor may be allowed to pay less than
the VA billed amount. In this regard,
under section 1729 a third party payor
has the option of paying, to the extent
of its coverage, either the billed charges
or the amount the third-party payor
would pay for the prescription drugs to
private sector providers in the same
geographic area. Accordingly, this
alternative will continue to be available
to third party payors in accordance with
the statutory mandate (see 38 CFR
17.101(a)(4)).
The commenter questioned how VA
will determine the price point within
the drug file and how this information
will be communicated to health plan
payers. We made no changes based on
this comment. The proposed rule stated
that the prescription cost will be
obtained from the Outpatient Pharmacy
Prescription file or the Drug file at each
VA facility (74 FR 32820). The product
cost of the prescription will be
calculated using the most recent
purchase price of the product used by
VA to fill the prescription. VA’s bill will
reflect the cost of the drugs, taking into
consideration the quantity dispensed
and VA’s national administrative cost.
The total prescription cost will be
transmitted on a bill to a third-party
payer.
In addition, the commenter also
questioned what billing claim field VA
will use for submitting cost information.
We made no changes based on this
comment. VA will combine the drug
costs plus administrative costs and
provide the total prescription cost in the
appropriate field in the form submitted,
e.g., National Council for Prescription
Drug Programs electronic format, UB04;
Centers for Medicare and Medicaid
Services (CMS) 1500.
The commenter also suggested that
VA have a graduated or phased
implementation so that third-party
payers will have time to absorb the
increased cost of payments. We do not
believe that a graduated or phased
implementation is necessary. Although
payments made to VA by third party
payors will represent an increase in the
PO 00000
Frm 00034
Fmt 4700
Sfmt 4700
amount of collections, we believe that
the overall impact on third party payors
will be minimal. In 2009, U.S sales of
prescription drugs totaled
approximately $300.3 billion. In
contrast, VA spent an estimated 4.9
billion on prescription drugs in 2009
(less than 2 per cent of the total sales).
A large portion of the prescription drugs
distributed in the U.S. are covered by
third party payors. However, with or
without the changes made by this rule,
VA would have collected less than $200
million in 2009 from third party payors.
Not only do we believe that the
overall impact to third party payors will
be minimal because of VA’s minimal
share, but as noted above, in some cases
a third party payor may be allowed to
pay less than the VA billed amount
based on the provisions in section 1729
which provide that a third party payor
has the option of paying, to the extent
of its coverage, either the billed charges
or the amount the third-party payor
would pay for the prescription drugs to
private sector providers in the same
geographic area.
The commenter suggested that the
final rule become effective only
prospectively, questioned when the
changes will become effective, and
expressed concerns regarding when VA
will make system changes necessary to
implement the final rule. We agree with
the commenter that the new billing
methodology should not be applied
retrospectively. This final rule is
effective March 18, 2011. The system
changes are scheduled to be in place on
that date. For further clarification, we
have added in the DATES section of this
document a statement indicating that
the final rule will apply to prescriptions
filled on or after the effective date of
this final rule. This will also provide
some lead time for third party payors to
prepare for compliance with the
amended regulations.
We also added a clarifying change in
paragraph (m). We inserted ‘‘regarding
VA charges’’ after ‘‘Notwithstanding
other provisions of this section’’ to
emphasize that paragraph (m) does not
concern other aspects of § 17.101, such
as the provisions of 38 CFR 17.101(a)(4),
which explain that a third-party payer’s
liability is limited, to the extent of its
coverage, to the lesser of the billed
charges or the amount that the thirdparty payer would pay to a provider
other than VA.
As required by 38 U.S.C.
1729(c)(2)(A), we consulted with the
Comptroller General of the United
States prior to promulgating this final
rule.
E:\FR\FM\06OCR1.SGM
06OCR1
Federal Register / Vol. 75, No. 193 / Wednesday, October 6, 2010 / Rules and Regulations
Unfunded Mandates
The Unfunded Mandates Reform Act
of 1995 requires, at 2 U.S.C. 1532, that
agencies prepare an assessment of
anticipated costs and benefits before
issuing any rule that may result in an
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $100 million or more
(adjusted annually for inflation) in any
year. This final rule will have no such
effect on State, local, and tribal
governments, or on the private sector.
WReier-Aviles on DSKGBLS3C1PROD with RULES
Paperwork Reduction Act
This document contains no
collections of information under the
Paperwork Reduction Act (44 U.S.C.
3501–3521).
Executive Order 12866
Executive Order 12866 directs
agencies to assess all costs and benefits
of available regulatory alternatives and,
when regulation is necessary, to select
regulatory approaches that maximize
net benefits (including potential
economic, environmental, public health
and safety, and other advantages;
distributive impacts; and equity). The
Executive Order classifies as a
‘‘significant regulatory action,’’ requiring
review by the Office of Management and
Budget (OMB), unless OMB waives such
review, as any regulatory action that is
likely to result in a rule that may: (1)
Have an annual effect on the economy
of $100 million or more or adversely
affect in a material way the economy, a
sector of the economy, productivity,
competition, jobs, the environment,
public health or safety, or State, local,
or tribal governments or communities;
(2) create a serious inconsistency or
otherwise interfere with an action taken
or planned by another agency; (3)
materially alter the budgetary impact of
entitlements, grants, user fees, or loan
programs or the rights and obligations of
recipients thereof; or (4) raise novel
legal or policy issues arising out of legal
mandates, the President’s priorities, or
the principles set forth in the Executive
Order.
VA has examined the economic,
interagency, budgetary, legal, and policy
implications of this final rule and has
concluded that it is a significant
regulatory action under Executive Order
12866 because it may raise novel legal
or policy issues arising out of legal
mandates, the President’s priorities, or
the principles set forth in the Executive
Order.
Regulatory Flexibility Act
The Secretary hereby certifies that
this final rule will not have a significant
economic impact on a substantial
VerDate Mar<15>2010
15:06 Oct 05, 2010
Jkt 223001
number of small entities as they are
defined in the Regulatory Flexibility
Act, 5 U.S.C. 601–612. This final rule
will mainly affect large insurance
companies. This final rule might have
an insignificant impact on a few small
entities that do an inconsequential
amount of their business with VA.
Therefore, pursuant to 5 U.S.C. 605(b),
this final rule is exempt from the initial
and final regulatory flexibility analysis
requirements of sections 603 and 604.
Catalog of Federal Domestic Assistance
Numbers
The Catalog of Federal Domestic
Assistance numbers and titles for the
programs affected by this document are
64.005, Grants to States for Construction
of State Home Facilities; 64.007, Blind
Rehabilitation Centers; 64.008, Veterans
Domiciliary Care; 64.009, Veterans
Medical Care Benefits; 64.010, Veterans
Nursing Home Care; 64.011, Veterans
Dental Care; 64.012, Veterans
Prescription Service; 64.013, Veterans
Prosthetic Appliances; 64.014, Veterans
State Domiciliary Care; 64.015, Veterans
State Nursing Home Care; 64.016,
Veterans State Hospital Care; 64.018,
Sharing Specialized Medical Resources;
64.019, Veterans Rehabilitation Alcohol
and Drug Dependence; 64.022, Veterans
Home Based Primary Care.
List of Subjects in 38 CFR Part 17
Administrative practice and
procedure, Alcohol abuse, Alcoholism,
Claims, Day care, Dental health, Drug
abuse, Foreign relations, Government
contracts, Grant programs—health,
Grant programs—veterans, Health care,
Health facilities, Health professions,
Health records, Homeless, Medical and
dental schools, Medical devices,
Medical research, Mental health
programs, Nursing homes, Philippines,
Reporting and recordkeeping
requirements, Scholarships and
fellowships, Travel and transportation
expenses, Veterans.
Editorial Note: This document was
received in the Office of the Federal Register
on September 30, 2010.
Approved: January 11, 2010.
John R. Gingrich,
Chief of Staff, Department of Veterans Affairs.
For the reasons stated in the preamble,
VA amends 38 CFR part 17 as follows:
■
2. Revise the second sentence of
paragraph (a)(2) and paragraph (m) of
§ 17.101 to read as follows:
■
§ 17.101 Collection or recovery by VA for
medical care or services provided or
furnished to a veteran for a nonserviceconnected disability.
(a) * * *
(2) * * * In addition, the charges
billed for prescription drugs not
administered during treatment will be
the amount determined under paragraph
(m) of this section. * * *
*
*
*
*
*
(m) Charges for prescription drugs not
administered during treatment.
Notwithstanding other provisions of this
section regarding VA charges, when VA
provides or furnishes prescription drugs
not administered during treatment,
within the scope of care referred to in
paragraph (a)(1) of this section, charges
billed separately for such prescription
drugs will consist of the amount that
equals the total of the actual cost to VA
for the drugs and the national average of
VA administrative costs associated with
dispensing the drugs for each
prescription. The actual VA cost of a
drug will be the actual amount
expended by the VA facility for the
purchase of the specific drug. The
administrative cost will be determined
annually using VA’s managerial cost
accounting system. Under this
accounting system, the average
administrative cost is determined by
adding the total VA national drug
general overhead costs (such as costs of
buildings and maintenance, utilities,
billing, and collections) to the total VA
national drug dispensing costs (such as
costs of the labor of the pharmacy
department, packaging, and mailing)
with the sum divided by the actual
number of VA prescriptions filled
nationally. Based on this accounting
system, VA will determine the amount
of the average administrative cost
annually for the prior fiscal year
(October through September) and then
apply the charge at the start of the next
calendar year.
*
*
*
*
*
[FR Doc. 2010–25043 Filed 10–5–10; 8:45 am]
BILLING CODE 8320–01–P
PART 17—MEDICAL
1. The authority citation for part 17
continues to read as follows:
■
Authority: 38 U.S.C. 501, 1721, and as
noted in specific sections.
PO 00000
Frm 00035
Fmt 4700
Sfmt 9990
61623
E:\FR\FM\06OCR1.SGM
06OCR1
Agencies
[Federal Register Volume 75, Number 193 (Wednesday, October 6, 2010)]
[Rules and Regulations]
[Pages 61621-61623]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-25043]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
38 CFR Part 17
RIN 2900-AN15
Charges Billed to Third Parties for Prescription Drugs Furnished
by VA to a Veteran for a Nonservice-Connected Disability
AGENCY: Department of Veterans Affairs.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This document amends the medical regulations of the Department
of Veterans Affairs (VA) concerning ``reasonable charges'' for medical
care or services provided or furnished by VA to a veteran for a
nonservice-connected disability. More specifically, VA amends the
regulations regarding charges billed for prescription drugs not
administered during treatment by changing the billing formula to
reflect VA's actual drug costs for each drug rather than using a
national average drug cost for all prescriptions dispensed. The revised
formula for calculating reasonable charges for prescription drug costs
will also continue to include an average administrative cost for each
prescription. The purpose is to provide VA with a more accurate billing
methodology for prescription drugs.
DATES: Effective Date: This final rule is effective on March 18, 2011.
Applicability Date: The final rule will apply to prescriptions
filled on or after March 18, 2011.
FOR FURTHER INFORMATION CONTACT: Romona Greene, Manager of Rates and
Charges, VHA Chief Business Office (168), Veterans Health
Administration, Department of Veterans Affairs, 810 Vermont Avenue,
NW., Washington, DC 20420, (202) 461-1595. (This is not a toll-free
number.)
SUPPLEMENTARY INFORMATION: Under 38 U.S.C. 1729, VA has the right to
recover or collect reasonable charges for medical care or services
(including the provision of prescription drugs) from a third party to
the extent that the veteran or the provider of the care or services
would be eligible to receive payment from the third party for:
A nonservice-connected disability for which the veteran is
entitled to care (or the payment of expenses of care) under a health
plan contract, 38 U.S.C. 1729(a)(2)(D), 38 CFR 17.101(a)(1)(i);
A nonservice-connected disability incurred incident to the
veteran's employment and covered under a worker's compensation law or
plan that provides reimbursement or indemnification for such care and
services, 38 U.S.C. 1729(a)(2)(A), 38 CFR 17.101(a)(1)(ii); or
A nonservice-connected disability incurred as a result of
a motor vehicle accident in a State that requires automobile accident
reparations (no-fault) insurance, 38 U.S.C. 1729(a)(2)(B), 38 CFR
17.101(a)(1)(iii).
However, under current 38 CFR 17.101(a)(4), which implements 38
U.S.C. 1729(c)(2)(B), a third-party payer liable for such medical care
and services under a health plan contract has the option of paying, to
the extent of its coverage, either the billed charges or the amount the
third-party payer demonstrates it would pay for care or services
furnished by providers other than entities of the United States for the
same care or services in the same geographic area.
Prior to the effective date of this document, VA billed for
prescription drugs not administered during treatment based on the sum
of two components: (1) The national average of VA's drug costs for all
prescriptions, and (2) the national average of VA's administrative
costs associated with furnishing prescription drugs. Further, in
accordance with Sec. 17.102(h), prior to the effective date of this
document, VA billed $51 for each prescription filled (see 70 FR 66866,
Nov. 3, 2005).
In a document published in the Federal Register on July 9, 2009 (74
FR 32819), we proposed to change the billing methodology for
prescription drugs not administered during treatment. With respect to
the portion of the billing concerning VA's cost for such prescription
drugs, we proposed to bill based on the actual cost to VA of each
prescription drug rather than the national average of drug costs for
all prescriptions. In this regard, we proposed to bill the total of:
[[Page 61622]]
The actual cost to VA for prescription drugs (i.e., the
cost to the facility that purchased the drugs); and
The average national administrative cost associated with
dispensing the drugs for each prescription.
We provided a 30-day comment period that ended on August 10, 2009.
We received comments from three commenters and the issues they raised
are discussed below. Based on the rationale set forth in the proposed
rule and this document, we are adopting the proposed rule with the
nonsubstantive changes discussed below.
Two commenters indicated that the final rule should ensure that
insurance companies pay VA in response to VA billing, and thereby
reduce or eliminate the veterans' copayment. We agree that the payment
practices of third-party payers need to be addressed. However, those
practices are not within the scope of this rulemaking. This rulemaking
concerns VA's methodology for determining reasonable charges for
prescription drugs. We did not propose to amend other VA regulations
regarding third-party payment procedures or to promulgate new
regulations regarding such procedures. However, we intend to separately
publish a proposed rule to address issues regarding requirements for
third-party payers making payments to VA.
Another commenter raised a number of issues. All of these issues
are discussed below.
The commenter indicated that the VA acquisition cost for
prescription drugs could be more than the third-party payer cost for
the same prescription drugs and seemed to suggest that the billing
amount for the cost of the drugs should not be more than the amount
that the third-party payer would be required to pay for the same
prescription drugs. The commenter also indicated that the VA
administrative fee of $11.17 is more than the average private
dispensing fee and that private industry has been successful in
negotiating such fees in the range of $1.50 to $2.00. We clarified what
is meant by administrative costs but made no other changes based on
these comments.
Under the provisions of 38 U.S.C. 1729, VA has authority to bill
third-party payers in an amount constituting ``reasonable charges.'' We
believe that the billing formula is warranted under the statute.
Moreover, VA has taken steps to keep costs at a minimum.
In most cases VA purchases drugs in bulk at discounted prices.
Also, insofar as possible, VA prescribes generic drugs.
Further, the $1.50 to $2.00 amounts quoted by the commenter were
represented as negotiated fees and not represented as covering the
actual administrative costs. We question whether these negotiated fees
include all of the actual administrative costs. The VA administrative
costs include general overhead costs, such as costs of buildings and
maintenance, utilities, billing, and collections, and includes
dispensing costs, such as costs of the labor of the pharmacy
department, packaging, and mailing.
Even so, in some cases, a third party payor may be allowed to pay
less than the VA billed amount. In this regard, under section 1729 a
third party payor has the option of paying, to the extent of its
coverage, either the billed charges or the amount the third-party payor
would pay for the prescription drugs to private sector providers in the
same geographic area. Accordingly, this alternative will continue to be
available to third party payors in accordance with the statutory
mandate (see 38 CFR 17.101(a)(4)).
The commenter questioned how VA will determine the price point
within the drug file and how this information will be communicated to
health plan payers. We made no changes based on this comment. The
proposed rule stated that the prescription cost will be obtained from
the Outpatient Pharmacy Prescription file or the Drug file at each VA
facility (74 FR 32820). The product cost of the prescription will be
calculated using the most recent purchase price of the product used by
VA to fill the prescription. VA's bill will reflect the cost of the
drugs, taking into consideration the quantity dispensed and VA's
national administrative cost. The total prescription cost will be
transmitted on a bill to a third-party payer.
In addition, the commenter also questioned what billing claim field
VA will use for submitting cost information. We made no changes based
on this comment. VA will combine the drug costs plus administrative
costs and provide the total prescription cost in the appropriate field
in the form submitted, e.g., National Council for Prescription Drug
Programs electronic format, UB04; Centers for Medicare and Medicaid
Services (CMS) 1500.
The commenter also suggested that VA have a graduated or phased
implementation so that third-party payers will have time to absorb the
increased cost of payments. We do not believe that a graduated or
phased implementation is necessary. Although payments made to VA by
third party payors will represent an increase in the amount of
collections, we believe that the overall impact on third party payors
will be minimal. In 2009, U.S sales of prescription drugs totaled
approximately $300.3 billion. In contrast, VA spent an estimated 4.9
billion on prescription drugs in 2009 (less than 2 per cent of the
total sales). A large portion of the prescription drugs distributed in
the U.S. are covered by third party payors. However, with or without
the changes made by this rule, VA would have collected less than $200
million in 2009 from third party payors.
Not only do we believe that the overall impact to third party
payors will be minimal because of VA's minimal share, but as noted
above, in some cases a third party payor may be allowed to pay less
than the VA billed amount based on the provisions in section 1729 which
provide that a third party payor has the option of paying, to the
extent of its coverage, either the billed charges or the amount the
third-party payor would pay for the prescription drugs to private
sector providers in the same geographic area.
The commenter suggested that the final rule become effective only
prospectively, questioned when the changes will become effective, and
expressed concerns regarding when VA will make system changes necessary
to implement the final rule. We agree with the commenter that the new
billing methodology should not be applied retrospectively. This final
rule is effective March 18, 2011. The system changes are scheduled to
be in place on that date. For further clarification, we have added in
the DATES section of this document a statement indicating that the
final rule will apply to prescriptions filled on or after the effective
date of this final rule. This will also provide some lead time for
third party payors to prepare for compliance with the amended
regulations.
We also added a clarifying change in paragraph (m). We inserted
``regarding VA charges'' after ``Notwithstanding other provisions of
this section'' to emphasize that paragraph (m) does not concern other
aspects of Sec. 17.101, such as the provisions of 38 CFR 17.101(a)(4),
which explain that a third-party payer's liability is limited, to the
extent of its coverage, to the lesser of the billed charges or the
amount that the third-party payer would pay to a provider other than
VA.
As required by 38 U.S.C. 1729(c)(2)(A), we consulted with the
Comptroller General of the United States prior to promulgating this
final rule.
[[Page 61623]]
Unfunded Mandates
The Unfunded Mandates Reform Act of 1995 requires, at 2 U.S.C.
1532, that agencies prepare an assessment of anticipated costs and
benefits before issuing any rule that may result in an expenditure by
State, local, and tribal governments, in the aggregate, or by the
private sector, of $100 million or more (adjusted annually for
inflation) in any year. This final rule will have no such effect on
State, local, and tribal governments, or on the private sector.
Paperwork Reduction Act
This document contains no collections of information under the
Paperwork Reduction Act (44 U.S.C. 3501-3521).
Executive Order 12866
Executive Order 12866 directs agencies to assess all costs and
benefits of available regulatory alternatives and, when regulation is
necessary, to select regulatory approaches that maximize net benefits
(including potential economic, environmental, public health and safety,
and other advantages; distributive impacts; and equity). The Executive
Order classifies as a ``significant regulatory action,'' requiring
review by the Office of Management and Budget (OMB), unless OMB waives
such review, as any regulatory action that is likely to result in a
rule that may: (1) Have an annual effect on the economy of $100 million
or more or adversely affect in a material way the economy, a sector of
the economy, productivity, competition, jobs, the environment, public
health or safety, or State, local, or tribal governments or
communities; (2) create a serious inconsistency or otherwise interfere
with an action taken or planned by another agency; (3) materially alter
the budgetary impact of entitlements, grants, user fees, or loan
programs or the rights and obligations of recipients thereof; or (4)
raise novel legal or policy issues arising out of legal mandates, the
President's priorities, or the principles set forth in the Executive
Order.
VA has examined the economic, interagency, budgetary, legal, and
policy implications of this final rule and has concluded that it is a
significant regulatory action under Executive Order 12866 because it
may raise novel legal or policy issues arising out of legal mandates,
the President's priorities, or the principles set forth in the
Executive Order.
Regulatory Flexibility Act
The Secretary hereby certifies that this final rule will not have a
significant economic impact on a substantial number of small entities
as they are defined in the Regulatory Flexibility Act, 5 U.S.C. 601-
612. This final rule will mainly affect large insurance companies. This
final rule might have an insignificant impact on a few small entities
that do an inconsequential amount of their business with VA. Therefore,
pursuant to 5 U.S.C. 605(b), this final rule is exempt from the initial
and final regulatory flexibility analysis requirements of sections 603
and 604.
Catalog of Federal Domestic Assistance Numbers
The Catalog of Federal Domestic Assistance numbers and titles for
the programs affected by this document are 64.005, Grants to States for
Construction of State Home Facilities; 64.007, Blind Rehabilitation
Centers; 64.008, Veterans Domiciliary Care; 64.009, Veterans Medical
Care Benefits; 64.010, Veterans Nursing Home Care; 64.011, Veterans
Dental Care; 64.012, Veterans Prescription Service; 64.013, Veterans
Prosthetic Appliances; 64.014, Veterans State Domiciliary Care; 64.015,
Veterans State Nursing Home Care; 64.016, Veterans State Hospital Care;
64.018, Sharing Specialized Medical Resources; 64.019, Veterans
Rehabilitation Alcohol and Drug Dependence; 64.022, Veterans Home Based
Primary Care.
List of Subjects in 38 CFR Part 17
Administrative practice and procedure, Alcohol abuse, Alcoholism,
Claims, Day care, Dental health, Drug abuse, Foreign relations,
Government contracts, Grant programs--health, Grant programs--veterans,
Health care, Health facilities, Health professions, Health records,
Homeless, Medical and dental schools, Medical devices, Medical
research, Mental health programs, Nursing homes, Philippines, Reporting
and recordkeeping requirements, Scholarships and fellowships, Travel
and transportation expenses, Veterans.
Editorial Note: This document was received in the Office of the
Federal Register on September 30, 2010.
Approved: January 11, 2010.
John R. Gingrich,
Chief of Staff, Department of Veterans Affairs.
0
For the reasons stated in the preamble, VA amends 38 CFR part 17 as
follows:
PART 17--MEDICAL
0
1. The authority citation for part 17 continues to read as follows:
Authority: 38 U.S.C. 501, 1721, and as noted in specific
sections.
0
2. Revise the second sentence of paragraph (a)(2) and paragraph (m) of
Sec. 17.101 to read as follows:
Sec. 17.101 Collection or recovery by VA for medical care or services
provided or furnished to a veteran for a nonservice-connected
disability.
(a) * * *
(2) * * * In addition, the charges billed for prescription drugs
not administered during treatment will be the amount determined under
paragraph (m) of this section. * * *
* * * * *
(m) Charges for prescription drugs not administered during
treatment. Notwithstanding other provisions of this section regarding
VA charges, when VA provides or furnishes prescription drugs not
administered during treatment, within the scope of care referred to in
paragraph (a)(1) of this section, charges billed separately for such
prescription drugs will consist of the amount that equals the total of
the actual cost to VA for the drugs and the national average of VA
administrative costs associated with dispensing the drugs for each
prescription. The actual VA cost of a drug will be the actual amount
expended by the VA facility for the purchase of the specific drug. The
administrative cost will be determined annually using VA's managerial
cost accounting system. Under this accounting system, the average
administrative cost is determined by adding the total VA national drug
general overhead costs (such as costs of buildings and maintenance,
utilities, billing, and collections) to the total VA national drug
dispensing costs (such as costs of the labor of the pharmacy
department, packaging, and mailing) with the sum divided by the actual
number of VA prescriptions filled nationally. Based on this accounting
system, VA will determine the amount of the average administrative cost
annually for the prior fiscal year (October through September) and then
apply the charge at the start of the next calendar year.
* * * * *
[FR Doc. 2010-25043 Filed 10-5-10; 8:45 am]
BILLING CODE 8320-01-P